AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23168367
Drug: R-CHOEP-14 (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOEP-14 (conventional chemotherapy with rituximab)
Trial: 23168367
Drug: R-MegaCHOEP (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-MegaCHOEP (high-dose chemotherapy with rituximab)
Trial: 17850608
Drug: Topical 20%
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 20% benzocaine gel
Trial: 10636366
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg daily for 50 days)
Trial: 7751733
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Lomefloxacin (LFLX)
Trial: 7751733
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Lomefloxacin (LFLX)
Trial: 2143361
Drug: Loratadine (Clarityn)
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine (Clarityn) 10 mg once daily
Trial: 2143361
Drug: Clemastine (Tavegyl)
RxNorm normalized name: clemastine Oral Tablet [Tavegil]
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clemastine (Tavegyl) 1 mg twice daily
Trial: 23924389
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (2000 IU daily) in DMT2 patients
Trial: 23924389
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Oral agents
Trial: 15500940
Drug: Fish gelatin
RxNorm normalized name: Fish Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish gelatin (3.61 g cumulative dose)
Trial: 15500940
Drug: Fish gelatin
RxNorm normalized name: Fish Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish gelatin (7.61 g cumulative dose)
Trial: 3292699
Drug: Live cold‐recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(7.9) EID50/ml
Trial: 3292699
Drug: Live cold‐recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(7.25) EID50/ml
Trial: 3292699
Drug: Live cold‐recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live cold‐recombinant influenza B virus vaccine (RB77) at 10(5.7) EID50/ml
Trial: 14578732
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of ursodeoxycholic acid daily for 6 months
Trial: 8970280
Drug: 20 gm
RxNorm normalized name: HYQVIA 20 GM / 200 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 gm supplement of All Bran and natural bran
Trial: 1473667
Drug: Midazolam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.03 mg/kg starting dose, titrated incrementally)
Trial: 1473667
Drug: Diazepam (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.10 mg/kg starting dose, titrated incrementally)
Trial: 6327927
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment with reinduction chemotherapy
Trial: 6327927
Drug: Three different
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three different chemotherapy regimens for remission induction
Trial: 30315403
Drug: Home-based or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based or group-based exercise (twice weekly for 1 year)
Trial: 22495338
Drug: Cognitive stimulation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive stimulation, physical activity, and socialization (active treatment group)
Trial: 28240592
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg BID in LTE studies
Trial: 28240592
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg BID in LTE studies
Trial: 25029428
Drug: Tapering prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering prednisolone for 6 months
Trial: 25029428
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for 3 months followed by matching-placebo for 3 months
Trial: 21483385
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (3 mg) before incision (MO1 group)
Trial: 21483385
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline before incision and morphine after wound closure (MO2 group)
Trial: 19760046
Drug: Nausea and
RxNorm normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nausea and vomiting, analgesic and antiemetic requirement, level of pain, quality of life
Trial: 25992639
Drug: Single-dose nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose nevirapine
Trial: 14530809
Drug: TAC (docetaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (docetaxel, doxorubicin, cyclophosphamide) 75/50/500 mg/m2 6xq3wk
Trial: 14530809
Drug: FAC (5‐fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC (5‐fluorouracil, doxorubicin, cyclophosphamide) 500/50/500 mg/m2 6x q3wk
Trial: 9145856
Drug: Aminosidine sulfate
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine sulfate (12 mg/kg)
Trial: 9145856
Drug: Aminosidine sulfate
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine sulfate (15 mg/kg)
Trial: 8181328
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipratropium and albuterol
Trial: 3695494
Drug: Fluoxymesterone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxymesterone (5 mg p.o. b.i.d.) for 3 days before and on the day of chemotherapy
Trial: 3695494
Drug: Cyclic i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic i.v. chemotherapy with cytoxan, adriamycin and 5-fluorouracil
Trial: 18691861
Drug: Budesonide-containing treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide-containing treatment
Trial: 18691861
Drug: Formoterol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol treatment
Trial: 12668406
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus exposure therapy
Trial: 9543786
Drug: Primary vaccination
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary vaccination (3 doses)
Trial: 9543786
Drug: Booster vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccination (1 dose) after vaccination 7 years earlier
Trial: 9543786
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with immune status based on past infection (3 doses)
Trial: 30701736
Drug: Nicorandil (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (30 mg/day for 2 days and 1 day before PCI, 20 mg 2 hours before PCI, 10 mg 6 hours after PCI)
Trial: 27296040
Drug: Dose-escalated concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated concurrent chemoradiotherapy (CRT) with tumor doses of 63 to 73 Gy in 30 once-daily fractions over 6 weeks with 2 concurrent cycles of cisplatin and vinorelbine.
Trial: 19944650
Drug: ALO-01 (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALO-01 (morphine sulfate and naltrexone hydrochloride)
Trial: 19944650
Drug: Extended-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release morphine sulfate (ERMS)
Trial: 16946602
Drug: Topical fluoride
RxNorm normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoride interventions
Trial: 12659989
Drug: Trimethazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethazidine (60 mg) + Diltiazem (90 mg)
Trial: 11126034
Drug: meperidine (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine (0.7 mg/kg) or midazolam (0.035 mg/kg) intravenously
Trial: 23541423
Drug: no medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no medication (control group)
Trial: 1388878
Drug: 200 IU
RxNorm normalized name: Vitamin E 200 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU nHuIFN alpha once daily orally for 6 weeks
Trial: 3902200
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to both treatments
Trial: 21635992
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg, BID for 12 weeks
Trial: 16117955
Drug: Lambdacyhalothrin residual
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lambdacyhalothrin residual house spraying (25 mg/m²)
Trial: 9596981
Drug: Phenylalanine 1
RxNorm normalized name: phenylalanine 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylalanine 1 g/d (58 subjects)
Trial: 9596981
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 g/d (38 subjects)
Trial: 8257205
Drug: Low power
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low power laser treatment (12 J/cm2 for 30 s, 12 treatments over four weeks)
Trial: 3928053
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump
Trial: 28253079
Drug: Yohimbine (α2‐adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (α2‐adrenoceptor antagonist)
Trial: 28253079
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Yohimbine and Hydrocortisone)
Trial: 25768023
Drug: Telecare intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telecare intervention (data uploaded daily to a nurse-led monitoring station)
Trial: 8554251
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 g of lactulose)
Trial: 8554251
Drug: Both fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both fiber preparations and lactulose
Trial: 1864100
Drug: Terbutaline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.5 mg) inhaled with positive expiratory pressure (PEP)
Trial: 1864100
Drug: Terbutaline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.5 mg) inhaled without PEP
Trial: 1864100
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray inhaled with PEP
Trial: 29417384
Drug: Agave fructans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agave fructans (96 mg/bw for 12 weeks)
Trial: 26997623
Drug: Protein isolates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein isolates (60 g/day)
Trial: 26997623
Drug: Maltodextrin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (60 g/day)
Trial: 20581351
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1 g/day) and Vitamin E (400 IU/day) supplementation during pregnancy
Trial: 12121931
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg i.v. b.i.d. on day 1 followed by 3 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 200 mg orally b.i.d. for days 8 to 14
Trial: 12121931
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg i.v. b.i.d. on day 1 followed by 5 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 400 mg orally b.i.d. for days 8 to 14
Trial: 12121931
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg i.v. b.i.d. on day 1 followed by 4 mg/kg i.v. b.i.d. on days 2 to 7, then switched to 300 mg orally b.i.d. for days 8 to 14
Trial: 7861219
Drug: ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (50 mg every 6 hours)
Trial: 7181805
Drug: Benactyzine hydrochloride
RxNorm normalized name: benactyzine hydrochloride
DrugBank: Benactyzine (DB09023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benactyzine hydrochloride (intramuscular administration)
Trial: 31533151
Drug: Amniotic Suspension
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amniotic Suspension Allograft (ASA)
Trial: 24463662
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D concentrations <30 nmol/L
Trial: 24463662
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D concentrations 50-74 nmol/L
Trial: 24463662
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D concentrations ≥75 nmol/L
Trial: 24463662
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D concentrations ≥50 nmol/L in white women
Trial: 24463662
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D concentrations ≥50 nmol/L in nonobese women
Trial: 10893378
Drug: Atropine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.01 mg/kg body weight, IM injection)
Trial: 10893378
Drug: Glycopyrrolate (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.005 mg/kg, IM injection)
Trial: 10893378
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution placebo (approximately 2 mL, IM injection)
Trial: 2884862
Drug: Pirmenol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirmenol 50 or 100 mg intravenously
Trial: 27831492
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of active treatment (WAT)
Trial: 18499600
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 0.5 microg/kg
Trial: 17646493
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 1 microg/kg
Trial: 16586550
Drug: Proton-pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump inhibitor (omeprazole or lansoprazole), clarithromycin, bismuth citrate and tinidazole
Trial: 16586550
Drug: Protective agent
RxNorm normalized name: PROTECTIVE AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective agent of gastric mucosa (tepretone)
Trial: 8808130
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg fluvoxamine
Trial: 8808130
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg dothiepin
Trial: 30275528
Drug: S-HAM (dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-HAM (dose-dense induction)
Trial: 27586232
Drug: Intravenous Magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Magnesium (Mg)
Trial: 22610193
Drug: Tight glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycemic control (80-110 mg/dL)
Trial: 22610193
Drug: Loose glycemic
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose glycemic control (120-150 mg/dL)
Trial: 8653874
Drug: L-carnitine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (500 mg IV as a single bolus)
Trial: 1558796
Drug: Early postoperative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early postoperative chemotherapy including mitomycin C (MMC), OK‐432, UFT, PSK, and 5‐fluorouracil (5‐FU) bolus injections for 5 days starting on postoperative day 2
Trial: 1558796
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving therapy with MMC, OK‐432, UFT, PSK without 5‐FU
Trial: 4026911
Drug: Azlocillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azlocillin (4 g, intravenous infusion over 5, 15, and 30 min)
Trial: 4026911
Drug: Mezlocillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (4 g, intravenous infusion over 5, 15, and 30 min)
Trial: 4026911
Drug: Both azlocillin
RxNorm normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both azlocillin and mezlocillin (4 g, intravenous infusion)
Trial: 31859723
Drug: Bacterial cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial cellulose biopolymer film and gel dressing
Trial: 12551869
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol intake (5 categories: no alcohol or <1 drink monthly, 1 to 3 drinks monthly, 1 to 4 drinks weekly, 5 to 7 drinks weekly, > or =2 drinks daily)
Trial: 8703660
Drug: Azapropazone 300
RxNorm normalized name: Azapropazone 300 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azapropazone 300 mg
Trial: 8703660
Drug: Azapropazone 600
RxNorm normalized name: Azapropazone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azapropazone 600 mg
Trial: 6424697
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium cromoglycate (SCG)
Trial: 6786129
Drug: Inhaled sodium
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sodium cromoglycate (SCG)
Trial: 25885285
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (monotherapy)
Trial: 25885285
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (combination therapy)
Trial: 17497439
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus 1 ng/kg/min iloprost
Trial: 9755350
Drug: Self-management program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management program for inhaler medication compliance (6 weeks)
Trial: 7663491
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (0.2 mg salbutamol plus 0.2 mg budesonide t.i.d.)
Trial: 7663491
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (0.2 mg salbutamol plus placebo t.i.d.)
Trial: 7663491
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group follow-up (28-36 months)
Trial: 7663491
Drug: Continuous group
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous group (continued treatment)
Trial: 2562087
Drug: pH adjusted
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH adjusted 2% mepivacaine solution (pHAS)
Trial: 2562087
Drug: Standard 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 2% mepivacaine solution
Trial: 368743
Drug: Progestogens (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestogens (single oral doses)
Trial: 31022403
Drug: Lanreotide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide (120 mg subcutaneously every 4 weeks)
Trial: 31022403
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (blood pressure control, sodium-restricted diet, antihypertensive agents)
Trial: 18413439
Drug: Local cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local cold therapy between -20 degrees C and -30 degrees C
Trial: 18413439
Drug: Local cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local cold therapy with glucocorticoids (GC)
Trial: 7912948
Drug: Neostigmine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 1.5 mg and atropine 0.5 mg
Trial: 12781313
Drug: Consultation‐Liaison Psychiatry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consultation‐Liaison Psychiatry (C‐L Psychiatry) intervention; early screening with systematic multidisciplinary management for emotional disorders.
Trial: 10940543
Drug: Pergolide 0.05
RxNorm normalized name: pergolide 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide 0.05 mg bid
Trial: 10940543
Drug: Pergolide 0.25
RxNorm normalized name: pergolide 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide 0.25 mg bid
Trial: 10940543
Drug: Pergolide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (both doses)
Trial: 3291787
Drug: Combined measles,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined measles, mumps, and rubella vaccine